2 Biotechs That Plunged More Than 20% Yesterday
After yesterday's big plunge in the stock market, and today with the Dow Jones Industrial Average dropping more than 500 points after opening, but mostly recovering, volatility appears to be…
After yesterday's big plunge in the stock market, and today with the Dow Jones Industrial Average dropping more than 500 points after opening, but mostly recovering, volatility appears to be…
The 28-year-old CEO of Ascendance Biomedical removed his trousers and injected himself at the BDYHAX conference in Texas. Source: BioSpace
According to sources reported by Reuters, potential buyers have been winnowed down to two pharma companies, three private equity funds, and a consortium of buyers. Source: BioSpace
Zogenix’s first global Phase 3 trial of ZX008, met the primary efficacy endpoint, as well as all prespecified key secondary efficacy endpoints. Source: BioSpace
The ACHIEVE I study included 1327 U.S. adult patients. Source: BioSpace
Genentech said the Phase III combination therapy improved progression-free survival by 26 percent in mRCC patients whose disease expressed a PD-L1 protein. Source: BioSpace
The company says the vaccine takes a novel approach. Source: BioSpace
The international clinical study, OPTIMISMM, achieved its primary endpoint. Source: BioSpace
The FDA hit Nexgen Pharma with a Form 483 after an inspection of its Irvine, California facility revealed procedural and documentation issues. Source: Drug Industry Daily
CDER denied a fourth petition from United Therapeutics calling on the center to impose additional conditions before approving ANDAs for combination products that reference its pulmonary arterial hypertension drug Tyvaso…